# Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

> **NCT07330076** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 28 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Iruplinalkib tablets

## Key facts

- **NCT ID:** NCT07330076
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-06
- **Primary completion:** 2030-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07330076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07330076, "Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07330076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*